Exercise of Stock Options and Total Voting Rights

21 November 2025

MicroSalt plc

("MicroSalt®" or the "Company")

Exercise of Stock Options and Total Voting Rights

MicroSalt plc (AIM: SALT), a leading provider of full-flavour natural salt with approximately 50% less sodium, announces that a total of 341,527 ordinary shares of £0.001625 each in the capital of the Company ("Ordinary Shares") ("Option Shares") have been allotted to two shareholders to satisfy the exercise of options over Ordinary Shares.

Options over an aggregate of 628,000 Ordinary Shares were exercised on a cashless basis under option agreements entered into in December 2021 and November 2022. Due to the cashless basis of the exercise a total of 341,527 Option Shares were allotted and issued. Pursuant to the terms of the option agreements, the exercise prices of the Option Shares were US$0.25 and US$0.545.

Application has been made to the London Stock Exchange for admission of the Option Shares to trading on AIM ("Admission"). It is expected that Admission will become effective on or around 26 November 2025.

Following the issue of the Option Shares, which on Admission will rank pari passu with the existing Ordinary Shares, the total number of Ordinary Shares in issue with voting rights in the Company will be 52,304,803. There are no Ordinary Shares held in treasury.

The above figure of 52,304,803 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

About MicroSalt

MicroSalt® is disrupting the global salt market with its patented, full-flavour, low-sodium salt designed for both food manufacturers and consumers. Using proprietary micron-sized particles, MicroSalt® delivers the same salty taste as traditional salt with approximately 50% less sodium, offering a scalable solution to one of the world's most pressing health challenges. Year to date through 2025, MicroSalt® has contributed to more than 634M servings made healthier.

Excess sodium consumption is a leading contributor to cardiovascular disease, the world's number one cause of death. The World Health Organisation has targeted a 30% reduction in global sodium intake by 2025, a shift projected to save seven million lives by 2030. The economic case is equally compelling: in the UK alone, cardiovascular disease costs £19 billion annually, and reducing average daily salt intake by just one gram could save over 4,000 lives and £288 million each year.

Operational since 2018, MicroSalt® has established a defensible IP portfolio, holding a granted US patent and 14 pending applications worldwide. These protections create significant barriers to entry in a market expected to grow exponentially as regulation and consumer demand accelerate.

MicroSalt® is ideally positioned for scale and market leadership, with clear pathways into food manufacturing, consumer channels, and ultimately the broader £10+ billion global salt market. MicroSalt® is more than a healthier alternative-it is a disruptive, category-defining solution poised to deliver significant commercial and societal impact.

For more information, please visit www.microsaltinc.co or follow on X @microSaltPLC.